MediciNova Receives a Notice of European Patent Allowance for Treating … – NASDAQ

MediciNova Receives a Notice of European Patent Allowance for Treating
NASDAQ
MediciNova's pipeline includes six clinical-stage compounds for the treatment of acute exacerbations of asthma, chronic obstructive pulmonary disease exacerbations, multiple sclerosis and other neurologic conditions, asthma, interstitial cystitis
MediciNova Receives Notice of European Patent Allowance for Treating Benzinga

all 3 news articles »

View full post on asthma – Google News

Positive Data on MediciNova’s MN-221 – Analyst Blog – NASDAQ

Positive Data on MediciNova's MN-221 – Analyst Blog
NASDAQ
MediciNova is developing MN-221, a highly selective beta(2)-adrenergic receptor agonist, for the treatment of acute exacerbations of asthma and COPD. In 2004, MediciNova licensed exclusive rights to MN-221 from Kissei Pharmaceutical Co., Ltd. in all
Drug trial signals hope for asthma sufferersSan Diego Source (subscription)
MediciNova Announces Positive Preliminary Results From a Multi-Day, Repeat MarketWatch (press release)
Illinois Investor Commits to Buy MediciNova StockSan Diego Business Journal

all 14 news articles »

View full post on asthma – Google News

MediciNova Announces Positive Preliminary Results From a Multi-Day, Repeat … – NASDAQ

MediciNova Announces Positive Preliminary Results From a Multi-Day, Repeat
NASDAQ
"There is a significant unmet medical need for an IV agent like MN-221 for asthma and COPD patients who are admitted to the ER due to a severe episode that is unresponsive to standard therapy," said Kazuko Matsuda, M.D., Ph.D., M.P.H, Chief Medical

and more »

View full post on asthma – Google News

MediciNova Enters Into a $20 Million Common Stock Purchase Agreement With … – NASDAQ

MediciNova Enters Into a $20 Million Common Stock Purchase Agreement With
NASDAQ
MediciNova will use the net proceeds from any sales of its stock to advance MediciNova's development activities for its lead programs, MN-221 (bedoradrine sulfate) in development for the treatment of acute asthma and chronic obstructive pulmonary

and more »

View full post on asthma – Google News

Pipeline Progresses at Glaxo/THRX – Analyst Blog – NASDAQ


InPharm

Pipeline Progresses at Glaxo/THRX – Analyst Blog
NASDAQ
The companies also completed the phase III Breo registrational program for the treatment of persistent asthma in adults and adolescents. Positive results were reported from a study evaluating the efficacy and safety of fluticasone furoate and
GSK and Theravance file for FF/VI approval in the USA and Europe; Talks with The Pharma Letter
GSK, Theravance seek approvals for FF/VI in US, EuropePharmaceutical Business Review
GSK and Theravance file COPD drugInPharm
Pharma Times
all 6 news articles »

View full post on asthma – Google News

Targacept Reports Revised Top-Line Results From Phase 2 Study Of TC-6987 – NASDAQ

Targacept Reports Revised Top-Line Results From Phase 2 Study Of TC-6987
NASDAQ
(RTTNews.com) – Targacept Inc. (TRGT) announced revised top-line results from its exploratory Phase 2 clinical study of TC-6987 in asthma. After identifying an error in the application of the agreed statistical analysis plan, a reanalysis of the data
Targacept Announces Revised Top-Line Results from Exploratory Phase 2 Study of MarketWatch (press release)
Targacept Announces Revised Top-Line Results from Exploratory Phase 2 StudyBenzinga

all 9 news articles »

View full post on asthma – Google News

GlaxoSmithKline Boosts Stake In Theravance To 27% – NASDAQ


RTT News

GlaxoSmithKline Boosts Stake In Theravance To 27%
NASDAQ
The move is said to be on the potential success of asthma drug Relovair, which is believed to be the successor of Seretide/Advair that logged sales of roughly $8.1 billion in 2011. Relovair is developed by Theravance and GlaxoSmithKline and is a
GlaxoSmithKline to Increase Its Ownership in TheravanceMarketWatch (press release)
GlaxoSmithKline invests $213M in Theravance Inc.Triangle Business Journal
Glaxo Lifts Theravance StakeWall Street Journal
MedCity News
all 34 news articles »

View full post on asthma – Google News

Biota Reports Positive Phase IIb Data For Asthmatic Patients With HRV Infection – NASDAQ

Biota Reports Positive Phase IIb Data For Asthmatic Patients With HRV Infection
NASDAQ
The Phase II multicenter, randomized, double-blind, placebo controlled study in asthmatic adults with symptomatic, naturally acquired human rhinovirus infection was conducted over two consecutive seasons in 48 centers in the US Subjects received either
Biota Announces Positive Phase IIb Data for Asthmatic Patients With Human MarketWatch (press release)

all 6 news articles »

View full post on asthma – Google News

Asthma and Second Hand Smoke

Press reports reflect that new studies suggests kids who live with a smoker are more likely to wheeze or get asthma, providing more evidence for the link between secondhand smoke and breathing problems.

Researchers found that the biggest effect on wheeze and asthma symptoms was seen in babies and toddlers whose moms smoked while they were pregnant or soon after kids were born.

The findings don’t prove that secondhand smoke caused kids to get asthma, but they add to other research suggesting smoke exposure may trigger respiratory problems in youngsters, researchers said.

“What this really clearly demonstrates is that the research and data documenting the adverse effects of tobacco smoke exposure on children’s asthma is very strong,” said Dr. Harold J. Farber, who studies smoking exposure and asthma at Baylor College of Medicine and Texas Children’s Hospital in Houston.

He said kids’ lungs may be weaker when they’re exposed to smoke in the womb, and asthma drugs may not work as well in those children.

“Eliminating our children’s tobacco exposure has got to be a critical public health priority,” Farber, who wasn’t involved in the report, told Reuters Health.

Researchers from the UK analyzed more than 70 studies published between 1997 and 2011, all of which asked about smoking by parents or other household members and then tracked which kids were diagnosed with wheezing or asthma going forward.

Those studies showed that when moms smoked while they were pregnant, their kids were 28 to 52 percent more likely to wheeze, depending on the age they were assessed. The effect on asthma symptoms was greatest in babies and toddlers, who were 85 percent more likely to have asthma if they were exposed to smoke in the womb.

When moms or non-parent household members smoked, kids had up to a 70 percent higher chance of wheezing through age four, but the link to full-on asthma was less clear. The effect of maternal smoking was weakest in kids age five to 18.

There was limited data on how smoking by dads affected kids’ chances of wheezing or getting asthma, according to findings published Monday in Pediatrics.

Tricia McKeever from the University of Nottingham and her colleagues said their findings suggest that secondhand smoke has more of an influence on wheeze and asthma than researchers had previously estimated.

“Before, (secondhand smoke) was known as triggering an attack or exacerbating asthma,” said Geoffrey Fong, a tobacco researcher from the University of Waterloo in Canada.

“This study shows that secondhand smoke may cause the development of asthma,” and not just trigger attacks in kids who already have it, said Fong, who wasn’t involved in the new study.